2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
200 recruiting
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Capacity Bio Inc. is a company with 2 orphan drug designations across 2 rare diseases. 5 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Duchenne muscular dystrophy | small molecule Mas receptor agonist | Des.TrialAppr. |
| amyotrophic lateral sclerosis | butyl ((2-(5-((1H-imidazol-1-yl)methyl)pyridin-2-yl)-4-(trifluoromethoxy)phenyl)sulfonyl) carbamate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
12
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
5
affecting portfolio
0% of portfolio targets high unmet need diseases
12
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
5
affecting portfolio